家族性高胆固醇血症一家系基因突变分析和临床治疗
DOI:
作者:
作者单位:

(1.扬州大学临床医学院,江苏省扬州市225001;2.江苏省苏北人民医院心血管内科,江苏省扬州市225001;3.江苏省苏北人民医院药学部,江苏省扬州市225001)

作者简介:

朱业,博士,副主任医师,研究方向为心脏起搏与电生理,E-mail:307971331@qq.com。通信作者刘佳,硕士,副主任药师,研究方向为心血管药物基因组学,E-mail:liujia85912@163.com。

通讯作者:

基金项目:

国家自然科学基金青年基金(81800250);中国博士后科学基金第71批次面上资助二等(2022M711417);江苏省研究型医院学会精益化用药-石药专项科研基金(JY202121);扬州市科技计划社会发展项目(YZ2023096)


Analysis of gene mutation and therapy in a family with familial hypercholesterolemia
Author:
Affiliation:

1.Clinical Medical College of Yangzhou University;2.Department of Cardiology, Northern Jiangsu People's Hospital;3.Department of Pharmacy, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的]总结1例家族性高胆固醇血症(FH)家系的基因突变分析和临床治疗方案。 [方法]先证者因“反复气喘伴胸痛4个月,加重2天”入院,血浆低密度脂蛋白胆固醇(LDLC)异常升高,且早发冠心病,对先证者进行全外显子测序和载脂蛋白E(ApoE)、对氧磷酶1(PON1)、前蛋白转化酶枯草溶菌素9(PCSK9)等位点进行测序分析,针对可疑致病突变在家系成员中进行检测,对先证者及其父亲进行了冠状动脉介入治疗和降脂治疗。 [结果]先证者、其父亲和其儿子在低密度脂蛋白受体(LDLR)基因中均检出了6个突变位点,分别为c.191+13G>A(rs200621482)、c.1598G>T(rs200427089)、c.883T>G(rs553235458)、c.3536A>G(rs201300867)、c.2215+6G>A(rs540060615)、c.162+5A>T(rs146596406)。这3例患者的6个位点均为杂合突变。3例患者的ApoE基因型结果如下:先证者及其儿子的ApoE基因型均为ε3/ε3型,蛋白表型为E3(ApoE2位点为CC型,ApoE4位点为TT型);其父亲的ApoE基因型为ε2/ε3型,蛋白表型为E2(ApoE2位点为CT型,ApoE4位点为TT型)。3例患者的PON1(A575G,rs662)位点基因型均为AG型,3例患者的PCSK9基因型为GG、CC、CC、GG型。基于该家系遗传学检测结果,给予先证者及其父亲个体化的降脂治疗方案,阿托伐他汀钙与依折麦布联合PCSK9抑制剂,且先证者及其父亲成功行冠状动脉介入治疗术,随访两年LDLC控制较好,未出现药物不良反应。 [结论]本研究中该家系患者的LDLR基因均发现6个位点突变,其中LDLR c.191+13G>A、c.162+5A>T在国内尚未见报道,丰富了中国人群的LDLR基因突变谱。本研究有利于阐明FH的发病机制,进一步指导FH患者的临床治疗。

    Abstract:

    Aim To summarize the gene mutation analysis and clinical treatment of a Chinese familial hypercholesterolemia family. Methods The proband was admitted to hospital due to “repeated asthma with chest pain for 4 months, aggravated for 2 days”, abnormally elevated plasma low density lipoprotein cholesterol (LDLC) and early onset of coronary heart disease. Whole exon sequencing was performed in the proband, and apolipoprotein E (ApoE), paraoxonase1(PON1), proprotein convertase subtilisin/kexin type 9 (PCSK9) and other sites were sequentially analyzed, and suspected pathogenic mutations were detected in family members. Coronary intervention and lipid-lowering therapy were performed in the proband and his father. Results The proband, his father and his son all had six mutations in the LDLR gene including c.191+13G>A(rs200621482), c.1598G>T(rs200427089), c.883T>G(rs553235458), c.3536A>G(rs201300867), c.2215+6G>A(rs540060615), c.162+5A>T(rs146596406), respectively. Heterozygous mutations were found in all 6 loci of the three patients. The ApoE genotypes of the three patients were as follows:ApoE genotypes of both the proband and his son were ε3/ε3, and the protein phenotype was E3 (CC at ApoE2 and TT at ApoE4); ApoE genotypes of his father was ε2/ε3, and the protein phenotype was E2(CT at ApoE2 and TT at ApoE4). The PON1(A575G, rs662) locus genotypes of three patients were AG, and the PCSK9 genotypes of three patients were GG, CC, CC and GG.Based on the results of the family genetic test, the proband and his father were given an individualized lipid-lowering regimen, atorvastatin calcium combined with ezetimibe and PCSK9 inhibitors, and the proband and his father were successfully treated with coronary interventionary therapy, and LDLC was normal with no adverse drug reactions during follow-up of two years. Conclusion In this study, 6 mutations of LDLR gene were found in all patients of this family, among which LDLR c.191+13G>A and c.162+5A>T were not reported in China, which enriched the mutation spectrum of LDLR gene in Chinese population. This study is helpful to elucidate the pathogenesis of FH and further guide the clinical treatment of FH patients.

    参考文献
    相似文献
    引证文献
引用本文

朱业,顾翔,朱华,刘佳.家族性高胆固醇血症一家系基因突变分析和临床治疗[J].中国动脉硬化杂志,2024,32(1):24~30.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2023-07-27
  • 最后修改日期:2023-09-25
  • 录用日期:
  • 在线发布日期: 2024-02-05